Truqap (capivasertib tablets – AstraZeneca) — Cigna

Breast Cancer

Initial criteria

Patient age ≥ 18 years
Patient has locally advanced or metastatic disease
Patient has hormone receptor-positive (HR+) disease
Patient has human epidermal growth factor receptor 2 (HER2)-negative disease
Patient has at least one phosphatidylinositol 3-kinase (PIK3CA), serine/threonine protein kinase (AKT1), or phosphatase and tensin homolog (PTEN)-alteration
Patient meets ONE of the following (i or ii):
i. Patient has had progression with at least one endocrine-based regimen in the metastatic setting AND progression with at least one cyclin-dependent kinase (CDK) 4/6 inhibitor in the metastatic setting
ii. Patient has recurrence on or within 12 months of completing adjuvant endocrine therapy

1 year